Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards
The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...
On-site inspections
BeiGene’s Tislelizumab Faces FDA Delay Due to Inspection Hurdles
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced a delay in the U.S. FDA’s decision...